NatWest Group plc Has $5.40 Million Position in Gilead Sciences, Inc. $GILD

NatWest Group plc cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 50.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,965 shares of the biopharmaceutical company’s stock after selling 44,590 shares during the quarter. NatWest Group plc’s holdings in Gilead Sciences were worth $5,396,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $26,000. Howard Hughes Medical Institute bought a new stake in Gilead Sciences during the second quarter worth about $30,000. MTM Investment Management LLC boosted its position in Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the last quarter. Kilter Group LLC acquired a new position in Gilead Sciences during the second quarter valued at approximately $33,000. Finally, Millstone Evans Group LLC grew its stake in Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 118 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at $76,504,230. This represents a 16.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This represents a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 309,280 shares of company stock valued at $44,068,850 in the last ninety days. Company insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Wolfe Research boosted their price target on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. HSBC increased their price objective on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Sanford C. Bernstein restated an “outperform” rating and set a $160.00 target price on shares of Gilead Sciences in a report on Wednesday, February 11th. Scotiabank upped their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, February 11th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research note on Monday, February 23rd. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $157.62.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $136.88 on Friday. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The firm has a market capitalization of $169.90 billion, a price-to-earnings ratio of 20.22, a P/E/G ratio of 1.81 and a beta of 0.37. The stock’s 50 day moving average price is $143.90 and its two-hundred day moving average price is $128.44. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.45%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.